Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41. 2005

Renaud Burrer, and Sandrine Haessig-Einius, and Anne-Marie Aubertin, and Christiane Moog
EA3770, Institut de Virologie, Université Louis Pasteur, 67000 Strasbourg, France.

We analyzed the factors influencing the binding of polyclonal immunoglobulin (Ig)G from HIV-infected patients to primary isolates (PI) in capture assays and a potential correlation between this binding and neutralization. The fixation of antibodies (Abs) to viral particles was measured by quantifying the capture of 4 PI by purified IgG immobilized onto a plate or by analyzing the capture of IgG-virus complexes formed in solution. We found that the capture of virus and the formation of immune complexes is mainly achieved by Abs directed against the principal immunodominant domain (PID) of gp41. We have further compared the binding measured by these two methods and the neutralizing activity of our polyclonal IgG and found no correlation. Thus, capture assays, including the immune complex capture assay that is more representative of "physiological" conditions, cannot be used as surrogate method for the investigation of the neutralizing activity of Abs.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007118 Immunoassay A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. Immunochromatographic Assay,Assay, Immunochromatographic,Assays, Immunochromatographic,Immunoassays,Immunochromatographic Assays
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014771 Virion The infective system of a virus, composed of the viral genome, a protein core, and a protein coat called a capsid, which may be naked or enclosed in a lipoprotein envelope called the peplos. Virus Particle,Viral Particle,Viral Particles,Particle, Viral,Particle, Virus,Particles, Viral,Particles, Virus,Virions,Virus Particles
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Renaud Burrer, and Sandrine Haessig-Einius, and Anne-Marie Aubertin, and Christiane Moog
October 1991, AIDS research and human retroviruses,
Renaud Burrer, and Sandrine Haessig-Einius, and Anne-Marie Aubertin, and Christiane Moog
December 2021, International immunopharmacology,
Renaud Burrer, and Sandrine Haessig-Einius, and Anne-Marie Aubertin, and Christiane Moog
March 2022, Communications biology,
Renaud Burrer, and Sandrine Haessig-Einius, and Anne-Marie Aubertin, and Christiane Moog
January 1994, Memorias do Instituto Oswaldo Cruz,
Renaud Burrer, and Sandrine Haessig-Einius, and Anne-Marie Aubertin, and Christiane Moog
May 2010, Journal of virology,
Renaud Burrer, and Sandrine Haessig-Einius, and Anne-Marie Aubertin, and Christiane Moog
January 2017, Frontiers in immunology,
Renaud Burrer, and Sandrine Haessig-Einius, and Anne-Marie Aubertin, and Christiane Moog
February 2014, Retrovirology,
Renaud Burrer, and Sandrine Haessig-Einius, and Anne-Marie Aubertin, and Christiane Moog
December 2010, Nature structural & molecular biology,
Renaud Burrer, and Sandrine Haessig-Einius, and Anne-Marie Aubertin, and Christiane Moog
March 1997, Acta crystallographica. Section D, Biological crystallography,
Renaud Burrer, and Sandrine Haessig-Einius, and Anne-Marie Aubertin, and Christiane Moog
November 1990, Journal of virology,
Copied contents to your clipboard!